Post-Hoc Analysis Supports Adjuvant Pembrolizumab in ccRCC at Increased Risk of Recurrence

Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis–free survival vs placebo in patients with clear cell renal cell carcinoma at increased risk of recurrence after nephrectomy, irrespective of UCLA Integrated Staging System risk category and disease stage.

Related Keywords

Massachusetts ,United States ,Dana Farber Cancer Institute ,Boston ,American ,Nancy Kohlberg ,Toni Choueiri ,Kidney Cancer Center ,Professor Of Medicine At Harvard Medical School ,Lank Center ,American Joint Committee On Cancer ,Staging System ,Cancers Symposium ,American Joint Committee ,Genitourinary Oncology ,Nancy Kohlberg Chair ,Harvard Medical School ,Pembrolizumab ,Clear Cell Renal Carcinoma ,Renal Cell Carcinoma ,Nrcc ,Ucla Integrated Staging System ,Guiss ,Nct03142334 ,Keynote 564 Trial ,Asco Gu ,